bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

PLOS ONE

Seroprevalence of brucellosis and characterisation of Brucella spp. from slaughtered cattle in Rwanda

--Manuscript Draft--

Manuscript Number:	
Article Type:	Research Article
Full Title:	Seroprevalence of brucellosis and characterisation of Brucella spp. from slaughtered cattle in Rwanda
Short Title:	Characterization of Brucella species from slaughtered cattle in Rwanda
Corresponding Author:	Jean Bosco Ntivuguruzwa, MSc University of Rwanda College of Agriculture Animal Sciences and Veterinary Medicine Kigali , RWANDA
Keywords:	Abattoirs; Brucella spp.; cattle; culture; PCR; serology; Rwanda
Abstract:	Bovine brucellosis is endemic in Rwanda, although, there is paucity of documented evidence about the disease in slaughtered cattle. A cross-sectional study was conducted in slaughtered cattle (n=300) to determine the seroprevalence of anti-Brucella antibodies using the Rose Bengal Test (RBT), and indirect enzyme-linked immunosorbent assay (i-ELISA). Corresponding tissues were cultured onto a modified Centro de Investigación y Tecnología Agroalimentaria (CITA) selective medium and analysed for Brucella spp. using the 16S-23S ribosomal interspacer region (ITS), AMOS, and Bruce-ladder PCR assays. The RBT seroprevalence was 20.7% (62/300), and 2.9% (8/300) with i-ELISA and 2.9% (8/300) using both tests in parallel. Brucella specific 16S-23S ribosomal DNA interspace region (ITS) PCR detected Brucella DNA in 5.6% (17/300; Brucella culture prevalence). AMOS-PCR assay identified mixed B. abortus and B. melitensis (n=3), B. abortus (n=3) and B. melitensis (n=5) while Bruce-ladder PCR also identified B. abortus (n=5) and B. melitensis (n=6). The gold standard culture method combined with PCR confirmation identified 5.6% Brucella cultures which is higher than the more sensitive seroprevalence of 2.9%. This emphasizes the need to validate the serological tests in Rwanda. The mixed infection caused by B. abortus and B. melitensis in slaughtered cattle indicates cross-infection and poses a risk of exposure potential to abattoir workers. It is essential to urgently strengthen the national bovine brucellosis control program through vaccination as well as test-and-slaughter.
Order of Authors:	Jean Bosco Ntivuguruzwa, MSc
	Francis Babaman Kolo, P.h.D
	Ivan Emil Mwikarago, P.h.D
	Henriette vanHeerden, P.h.D
Opposed Reviewers:	Karama Karama, Ph.D Senior lecturer, University of Pretoria Faculty of Veterinary Science musafiri.karama@up.ac.za He has been very bad to me when I was doing my masters. He refused me to publish my three articles.
Additional Information:	
Question	**Response**
Financial Disclosure Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the submission guidelines for detailed requirements. View published research	HvH received funds from the Institute of Tropical Medicine Antwerp (https://www.itg.be) in collaboration with the Department of Veterinary Tropical Diseases (https://www.up.ac.za/veterinary-tropical-diseases).

Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

articles from *PLOS ONE* for specific examples. This statement is required for submission and **will appear in the published article** if the submission is accepted. Please make sure it is accurate. **Unfunded studies** Enter: *The author(s) received no specific funding for this work.* **Funded studies** Enter a statement with the following details: • Initials of the authors who received each award • Grant numbers awarded to each author • The full name of each funder • URL of each funder website • Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript? • **NO** - Include this sentence at the end of your statement: *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.* • **YES** - Specify the role(s) played. * typeset	
Competing Interests Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors, disclose any competing interests that could be perceived to bias this work—acknowledging all financial support and any other relevant financial or non-financial competing interests. This statement is required for submission and **will appear in the published article** if the submission is accepted. Please make sure it is accurate and that any funding sources listed in your Funding Information later in the submission form are also declared in your Financial Disclosure statement.	The authors declare that there are no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

View published research articles from *PLOS ONE* for specific examples. **NO authors have competing interests** Enter: *The authors have declared that no competing interests exist.* **Authors with competing interests** Enter competing interest details beginning with this statement: *I have read the journal's policy and the authors of this manuscript have the following competing interests: [insert competing interests here]* * typeset	
Ethics Statement Enter an ethics statement for this submission. This statement is required if the study involved: • Human participants • Human specimens or tissue • Vertebrate animals or cephalopods • Vertebrate embryos or tissues • Field research Write "N/A" if the submission does not require an ethics statement. General guidance is provided below. Consult the submission guidelines for detailed instructions. **Make sure that all information entered here is included in the Methods section of the manuscript.**	The authorization to conduct the study was obtained from the research screening and ethical clearance committee of the College of Agriculture, Animal Sciences and Veterinary Medicine, University of Rwanda (Ref:026/DRIPGS/2017), institutional review board of the College of Medicine and Health Sciences, University of Rwanda (No 006/CMHS IRB/2020), and Animal Ethics Committee of the Faculty of Veterinary Science, University of Pretoria, South Africa (V004/2020).

Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Format for specific study types **Human Subject Research (involving human participants and/or tissue)** • Give the name of the institutional review board or ethics committee that approved the study • Include the approval number and/or a statement indicating approval of this research • Indicate the form of consent obtained (written/oral) or the reason that consent was not obtained (e.g. the data were analyzed anonymously) **Animal Research (involving vertebrate animals, embryos or tissues)** • Provide the name of the Institutional Animal Care and Use Committee (IACUC) or other relevant ethics board that reviewed the study protocol, and indicate whether they approved this research or granted a formal waiver of ethical approval • Include an approval number if one was obtained • If the study involved *non-human primates*, add *additional details* about animal welfare and steps taken to ameliorate suffering • If anesthesia, euthanasia, or any kind of animal sacrifice is part of the study, include briefly which substances and/or methods were applied **Field Research** Include the following details if this study involves the collection of plant, animal, or other materials from a natural setting: • Field permit number • Name of the institution or relevant body that granted permission	
Data Availability Authors are required to make all data underlying the findings described fully available, without restriction, and from the time of publication. PLOS allows rare exceptions to address legal and ethical concerns. See the PLOS Data Policy and FAQ for detailed information.	Yes - all data are fully available without restriction

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

<table>
<tr><td>A Data Availability Statement describing where the data can be found is required at submission. Your answers to this question constitute the Data Availability Statement and will be published in the article, if accepted.

Important: Stating ‘data available on request from the author’ is not sufficient. If your data are only available upon request, select ‘No’ for the first question and explain your exceptional situation in the text box.

Do the authors confirm that all data underlying the findings described in their manuscript are fully available without restriction?</td><td></td></tr>
<tr><td>Describe where the data may be found in full sentences. If you are copying our sample text, replace any instances of XXX with the appropriate details.

• If the data are held or will be held in a public repository, include URLs, accession numbers or DOIs. If this information will only be available after acceptance, indicate this by ticking the box below. For example: All XXX files are available from the XXX database (accession number(s) XXX, XXX.).
• If the data are all contained within the manuscript and/or Supporting Information files, enter the following: All relevant data are within the manuscript and its Supporting Information files.
• If neither of these applies but you are able to provide details of access elsewhere, with or without limitations, please do so. For example:

Data cannot be shared publicly because of [XXX]. Data are available from the XXX Institutional Data Access / Ethics Committee (contact via XXX) for researchers who meet the criteria for access to confidential data.

The data underlying the results presented in the study are available from (include the name of the third party</td><td>All relevant data are within the manuscript and its Supporting Information files.</td></tr>
</table>

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

and contact information or URL). • This text is appropriate if the data are owned by a third party and authors do not have permission to share the data. * typeset	
Additional data availability information:	Tick here if your circumstances are not covered by the questions above and you need the journal's help to make your data available.

Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation

Cover Letter bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

College of Agriculture and Veterinary Medicine,
Department of Veterinary Medicine

December 4th, 2021

To: Editor/ PLOS ONE

Re: Submission of manuscript

Enclosed is a manuscript to be considered for publication in PLOS ONE. The title of the manuscript is "seroprevalence of brucellosis and molecular characterization of *Brucella* spp. from slaughtered cattle in Rwanda". Bovine brucellosis is a zoonotic disease that is prevalent in the cattle population in Rwanda. However, there is not sufficient data about the seroprevalence and *Brucella* spp. circulating in Rwandan cattle. We investigated the seroprevalence of brucellosis and characterized *Brucella* spp. from slaughtered cattle in Rwanda. Our findings demonstrated the overall seroprevalence of 2.9% (8/300) using the Rose Bengal Test and indirect ELISA in parallel. The culture prevalence confirmed with *Brucella* specific 16S-23S ribosomal DNA interspace region (ITS) PCR was 5.6% (17/300). AMOS-PCR assay identified mixed *B. abortus* and *B. melitensis* (n=3), *B. abortus* (n=3) and *B. melitensis* (n=5) while Bruce-ladder PCR confirmed *B. abortus* (n=5) and *B. melitensis* (n=6). The gold standard culture method combined with PCR confirmation (5.6%) was higher than the more sensitive seroprevalence of 2.9%. This emphasizes the need to validate the serological tests in Rwanda. The mixed infection caused by *B. abortus* and *B. melitensis* in slaughtered cattle indicates cross-infection and poses a risk of exposure potential to abattoir workers. It is essential to urgently strengthen the national bovine brucellosis control program through vaccination as well as test-and-slaughter.

This manuscript is an original work that meets the scope and aims of the PLOS ONE and has not been submitted to any journal for publication.

I am Jean Bosco Ntivuguruzwa, a corresponding author on behalf of all other co-authors.

Yours sincerely

Jean Bosco Ntivuguruzwa, the corresponding Author

Manuscript bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Click here to access/download;Manuscript;Manuscript .docx

1 # Seroprevalence of brucellosis and molecular
2 # characterization of *Brucella* spp. from slaughtered cattle
3 # in Rwanda

4 Jean Bosco Ntivuguruzwa [1, 2 ¶]; Francis Babaman Kolo[1&]; Emil Ivan Mwikarago[3#a &]; Henriette
5 vanHeerden[1¶]

6 [1]Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of
7 Pretoria; Pretoria, South Africa

8 [2]Department of Veterinary Medicine, College of Veterinary Medicine, University of Rwanda,
9 Kigali, Rwanda

10 [3]Department of Biomedical Services, National Reference Laboratory Division, Rwanda
11 Biomedical Centre, Kigali, Rwanda

12 [#a]Current address: Department of Lab Sciences, College of Medicine and Health Sciences,
13 University of Rwanda, Kigali, Rwanda

14 * Corresponding author

15 Corresponding author: boscus2@gmail.com, +250788648909

16 ¶ These authors contributed equally to this work

17 & These authors also contributed equally to this work

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Abstract

Bovine brucellosis is endemic in Rwanda, although, there is paucity of documented evidence about the disease in slaughtered cattle. A cross-sectional study was conducted in slaughtered cattle (n=300) to determine the seroprevalence of anti-*Brucella* antibodies using the Rose Bengal Test (RBT), and indirect enzyme-linked immunosorbent assay (i-ELISA). Corresponding tissues were cultured onto a modified Centro de Investigación y Tecnología Agroalimentaria (CITA) selective medium and analysed for *Brucella* spp. using the 16S-23S ribosomal interspacer region (ITS), AMOS, and Bruce-ladder PCR assays. The RBT seroprevalence was 20.7% (62/300), and 2.9% (8/300) with i-ELISA and 2.9% (8/300) using both tests in parallel. *Brucella* specific 16S-23S ribosomal DNA interspace region (ITS) PCR detected *Brucella* DNA in 5.6% (17/300; *Brucella* culture prevalence). AMOS-PCR assay identified mixed *B. abortus* and *B. melitensis* (n=3), *B. abortus* (n=3) and *B. melitensis* (n=5) while Bruce-ladder PCR also identified *B. abortus* (n=5) and *B. melitensis* (n=6). The gold standard culture method combined with PCR confirmation identified 5.6% *Brucella* cultures which is higher than the more sensitive seroprevalence of 2.9%. This emphasizes the need to validate the serological tests in Rwanda. The mixed infection caused by *B. abortus* and *B. melitensis* in slaughtered cattle indicates cross-infection and poses a risk of exposure potential to abattoir workers. It is essential to urgently strengthen the national bovine brucellosis control program through vaccination as well as test-and-slaughter.

Keywords

Abattoirs; *Brucella* spp.; cattle; culture; PCR; serology; Rwanda

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

39 # Introduction

40 Brucellosis is a contagious widespread disease that causes not only substantial economic
41 losses related to abortions, long conception intervals, and sterility in animals but also morbidity
42 and reduced working capacity in humans (1, 2). The disease is caused by bacteria of the genus
43 *Brucella* which belongs to the family of alphaproteobacteria (3). *Brucella* species are gram-negative
44 microaerophilic coccobacilli, acid-fast intracellular, and hosts-specific microorganisms affecting
45 a wide variety of terrestrial and marine mammals (4, 5). *Brucella* species are 96% genetically
46 identical (6) with few polymorphisms that are essential for species and biovars differentiation (7,
47 8). Classical species with their biovars (bv.) have specific hosts, for instance, *B. abortus* (7 biovars)
48 infect primarily cattle, *B. melitensis* (3 biovars) infect goats and sheep, *B. ovis* infect sheep, *B. suis*
49 (bv. 1, 3, 4, and 5) infect swine while *B. suis* bv. 2 infects rats, *B. canis* infects dogs, and *B. neotomae*
50 infects wood rats (4, 9).

51 The transmission of brucellosis in animals is through inhalation of *Brucella* aerosols (10),
52 direct contact with infective foetal membranes, vaginal discharges, placenta content, and
53 ingestion of contaminated feeds (11). There are no pathognomonic clinical signs for brucellosis,
54 but cases of abortion or hygroma are suspicious signs that require laboratory diagnosis for
55 confirmation (9, 12).

56 As brucellosis is a herd disease, the most suitable tests are serological tests to determine
57 the seroprevalence of brucellosis in the animal and or herd using a screening agglutination test,
58 the Rose Bengal Test (RBT), and a confirmatory test like enzyme-linked immunosorbent assays

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

59 (ELISAs) or complement fixation test (CFT) (9). However, serological tests do not provide a
60 complete diagnosis, thus, the isolation of *Brucella* spp. remains the gold standard (9). The
61 culturing and biotyping of *Brucella* cultures are expensive, time-consuming, and require trained
62 personnel (7). PCR assays which differentiate *B. abortus* bv.1, 2, 4, *B. melitensis* bv.1, 2, 3, *B. ovis*,
63 and *B. suis* bv.1 (AMOS PCR) in 24 hours from cultures (7) and Bruce-ladder PCR assay can
64 differentiate all *Brucella* species and vaccine strains (13, 14). Unfortunately, culture, phenotypic
65 and genotypic isolation of *Brucella* spp. are not common in veterinary services in most developing
66 countries owing to inadequate facilities and trained personnel; therefore, serology is in common
67 practice with little knowledge on the type of infecting *Brucella* spp. (15).

68 Brucellosis is an endemic disease in Rwanda with a reported 7.4% to 18.7% seroprevalence
69 in cattle (16, 17), as well as seroprevalence in women with a history of abortions varying between
70 6.1% and 25.0% (18, 19). Although, cattle from various districts of the country are slaughtered at
71 abattoirs, there is no single study on the seroprevalence of brucellosis in slaughtered cattle in
72 Rwanda. Furthermore, apart from a single study that isolated *B. abortus* bv. 3 from Rwandan cattle
73 in the 1980s (20), *Brucella* spp. that are circulating in Rwanda are not known. The objective of this
74 study was, therefore, to determine the seroprevalence of brucellosis and characterize *Brucella* spp.
75 from slaughtered cattle in Rwanda. Our findings are essential to building an epidemiological
76 database essential for the control of brucellosis in Rwanda.

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

77 # Materials and methods

78 ## Study area

79 This study was conducted at six abattoirs in Rwanda. Rwanda is a landlocked country of
80 the East African community covering an area of 26,338 Km^2 in the southern hemisphere near the
81 equator (West: 28.86; East: 30.89; North: - 1.04; South: - 2.83). The bovine population in Rwanda
82 was estimated at 1,293,768 in 2018 (21). The six abattoirs (société des abattoirs de Nyabugogo
83 "SABAN", Rugano abattoir, Kamembe, Rubavu, Kamuhanda, Gataraga) consented to participate
84 (Fig 1). These abattoirs were selected based on their slaughtering capacity and their location to
85 sample cattle from all the thirty districts of Rwanda. In this study, cattle sampled at SABAN
86 abattoir were from 19 districts including Rulindo, Ngoma, Muhanga, Nyagatare, Gasabo,
87 Bugesera, Ngororero, Gakenke, Burera, Rutsiro, Gicumbi, Nyarugenge, Kirehe, Ruhango,
88 Kayonza, Karongi, Nyanza, Kamonyi, and Gatsibo. Cattle sampled at Rugano abattoir were from
89 three districts including Gasabo, Rwamagana, and Nyarugenge. Cattle sampled at Kamembe
90 abattoir were from eight districts including Gisagara, Huye, Nyamagabe, Nyamasheke, Nyanza,
91 Nyaruguru, Ruhango, and Rusizi. Cattle sampled at Rubavu abattoir were from two districts
92 including Nyabihu, and Rubavu. Cattle sampled at Kamuhanda abattoir were from the Kamonyi
93 district. Cattle sampled at Gataraga abattoir were from the Musanze district. These abattoirs were
94 classified into high throughput abattoirs (n = 4) slaughtering more than 50 cattle daily and low
95 throughput abattoirs (n = 2) slaughtering 50 or less every day.

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

96 Fig 1. Map of provinces and districts of Rwanda with location (red asterisks) of abattoirs visited
97 during this study.

98 Study design and sample size

99 A cross-sectional study was carried out from August 2018 through October 2019 to
100 determine the seroprevalence of brucellosis and characterize *Brucella* spp. from cattle tissue
101 selected during slaughtering at abattoirs. The sample size was calculated using the previously
102 described formula (22) for cross-sectional studies.

103 $$N = \frac{Z^2 \ \ P(1-P)}{d^2}$$

104 Where N is the sample size, Z^2 = 1.96 the statistical constant at 95% confidence interval; P is the
105 expected prevalence and was estimated at 0.5%, and the absolute precision, d = (P/2). According
106 to the formula, the total sample size was 291 but it was rounded to 300 cattle to sample ten animals
107 per each of the 30 districts of Rwanda.

108 Sampling procedure

109 Our target was to sample five animals coming from the same district every day. The
110 district of origin of animals was recorded on arrival using the movement permit issued by the
111 sector animal resources officer at the animal market. The age was determined using teeth erosion
112 as previously described (23). Except for abattoirs that received mostly males, females of one year
113 and above were selected using a systematic random sampling. Animals were aligned in a crush

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

114 and every fourth animal was selected for sampling. The vaccination status and farm of origin of
115 slaughtered animals could not be traced because most of the animals were bought from the
116 different animal markets.

117 Collection of blood and tissues samples

118 After the selection and recording of individual demographic information (district of
119 origin, age, breed, and sex), the animal was restrained, marked on the head, and released for
120 resting waiting for the collection of blood after bleeding. Blood was collected into sterile 50 ml
121 tubes after slaughter, aliquoted into 5 ml tubes and was immediately transported to the
122 laboratory of the University of Rwanda (UR) and left overnight at room temperature to allow
123 clotting. The following day, serum was collected into a sterile 2 ml micro-centrifuge tube and
124 stored at -20°C until serological testing at Rwanda Agriculture and Animal Resources Board
125 (RAB), Department of Veterinary Services, in the serology section. The head of the marked animal
126 from which blood was collected was followed at head inspection station and the corresponding
127 left and right retropharyngeal lymph nodes were collected into a sterile 50 ml tube.

128 Serological tests

129 Animal sera were tested with the RBT following the manufacturer's guidelines (IDvet,
130 France) and the OIE protocol (9). Briefly, equal volumes (30 μl) of *Brucella* antigens and sera were
131 gently mixed for four minutes, and any agglutination was regarded as a positive result. All sera
132 were also checked for the presence of anti-*Brucella* antibodies with a confirmatory test kit namely

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

133 a multispecies i-ELISA according to manufacturer's guidelines (IDvet, France) and the OIE
134 protocol (9) with positive and negative controls. The cut-off point for the seropositivity was 120%
135 and sera samples having 120% of optical densities were considered positive. These serological
136 tests were chosen because of their combined effects of sensitivity and specificity (24). RBT is a
137 screening test with high sensitivity, while i-ELISA is a confirmatory test with high specificity (24,
138 25). Any detection of anti-*Brucella* antibodies by RBT or i-ELISA was considered to determine the
139 seroprevalence of brucellosis.

140 Culturing and *Brucella* isolation from tissues

141 Tissue samples were processed and cultured in a biosafety level 3 (BSL 3) facility at the
142 National Reference Laboratory (NRL), Rwanda Biomedical Centre (RBC), Kigali, Rwanda
143 according to the guidelines previously described (9). Briefly, tissues were sliced using sterile
144 scissors and forceps into sterile mortars and grounded using a sterile pestle. An aliquot of pooled
145 homogenate was spread into a modified Centro de Investigación y Tecnología Agroalimentaria
146 (CITA) selective medium and incubated at 37°C with 10.0% CO_2 atmosphere (26). Plates were
147 read for bacterial growth every day for four weeks. The DNA was extracted from colonies suspect
148 of *Brucella* organisms.

149 DNA extraction and identification of the genus *Brucella* spp.

150 Genomic DNA was extracted from cultures using the ReliaPrep gDNA tissue Miniprep
151 system following the manufacturer's guidelines (Promega, USA). This DNA was screened for

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

152 *Brucella* DNA using *Brucella* specific primers (Table 1) designed from a gene-specific 16S -23S
153 rDNA interspacer region (ITS) (27) with the *B. abortus* RF 544 (Onderstepoort Biological Products,
154 South Africa) as a positive control. The 15 µl PCR reaction mixture contained 1x of MyTaq™ Red
155 PCR Mix (Bioline, South Africa), primers at 0.2 µM, and 2 µl of template DNA. The PCR cycling
156 condition was initial denaturation at 95°C for 3 min followed by 35 cycles of denaturation at 95°C
157 for 1 min, annealing at 60°C for 2 min, and extension at 72°C for 2 min and a final extension step
158 at 72°C for 5 min. The primers amplified a 214 bp fragment that was analyzed by electrophoresis
159 using a 2% agarose gel stained with red gel nucleic acid stain and visualized under UV light.
160 Molecular analyses were done at the Department of Veterinary Services, Rwanda Agriculture
161 Board (RAB) Kigali, Rwanda.

162 Identification of *Brucella* species using AMOS and Bruce-ladder PCR 163 assays

164 The DNA samples that were ITS PCR positive were tested for *B. abortus*, *B. melitensis*, *B.*
165 *ovis*, and *B. suis* using a multiplex AMOS PCR assay as previously described (7). A 25 µl reaction
166 mixture contained 1x MyTaq Red PCR Mix (Bioline, South Africa), four species-specific forward
167 primers and reverse primer IS711 (Table 1) at a final concentration of 0.1 µM and 0.5 µM
168 respectively, and 2 µl of template DNA. Thermocycling conditions included initial denaturation
169 at 95°C for 3 min followed by 35 cycles of denaturation at 95°C for 1 min, annealing at 60°C for 2
170 min, an initial extension at 72°C for 2 min, and a final extension at 72°C for 5 min. PCR products

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

171 were analysed by gel electrophoresis using 2% agarose stained with red gel nucleic acid stain and
172 visualized under UV light.

173 Vaccine strains and field isolates of *Brucella* spp. were identified and differentiated by a
174 multiplex Bruce-ladder PCR as previously described (14). A 25 µl PCR reaction contained 1x
175 MyTaq™ Red Mix (Bioline, South Africa), eight species-specific forward and reverse primers at a
176 final concentration of 6.25 µM (Table 1), and 5 µl of template DNA. The PCR cycling conditions
177 included an initial denaturation at 95°C for 5 min followed by 25 cycles of at 95°C for 30 s, at 64°C
178 for 45 s, and at 72°C for 3 min and a final extension step at 72°C for 10 min. PCR products were
179 analysed by gel electrophoresis using a 2% agarose stained with gel red nucleic acid stain and
180 viewed under UV light.

181 Data analysis

182 The overall seroprevalence was obtained by dividing the total number of animals
183 simultaneously positive to RBT and i-ELISA by the total number of animals sampled. Data were
184 recorded in Microsoft Excel spreadsheets. Epi-Info 7 version 10 was used to calculate proportions.
185 Significant levels between individual risk factors and seroprevalence and molecular results were
186 determined using the chi-square test. The odds-ratios were determined for associated risk factors
187 along 95% confidence intervals and statistical significance set at $p < 0.05$.

188 Ethics clearance

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

189 The authorization to conduct the study was obtained from the research screening and
190 ethical clearance committee of the College of Agriculture, Animal Sciences and Veterinary
191 Medicine, University of Rwanda (Ref:026/DRIPGS/2017), institutional review board of the
192 College of Medicine and Health Sciences, University of Rwanda (N° 006/CMHS IRB/2020), and
193 Animal Ethics Committee of the Faculty of Veterinary Science, University of Pretoria, South
194 Africa (V004/2020). Informed verbal consent was obtained from managers of abattoirs, and
195 owners of animals at the abattoirs.

196 Table 1: Sequences of oligonucleotide primers used for the distinction of *Brucella* species isolated from slaughtered cattle in Rwanda

197

PCR name	Primer name	Sequence (5'-3')	Targets	Size (bp)	Conc. (µM)	References
ITS	ITS66 f	ACATAGATCGCAGGCCAGTCA	*16s-23s rDNA*	214	0.2	(27)
	ITS279 r	ACATAGATCGCAGGCCAGTCA				
AMOS	*B. abortus*	GAC GAA CGG AAT TTT TCC AAT CCC	IS711	498	0.1	(7)
	B. melitensis	AAA TCG CGT CCT TGC TGG TCT GA		731	0.1	
	B. ovis	CGG GTT CTG GCA CCA TCG TCG GG		976	0.1	
	B. suis	GCG CGG TTT TCT GAA GGT GGT TCA		285	0.1	
	IS 711	TGC CGA TCA CTT AAG GGC CTT CAT			0.2	
BRUCE- LADDER	BMEI0998f	ATC CTA TTG CCC CGA TAA GG	*wboA*	1682	6.25	(28, 29)
	BMEI0997r	GCT TCG CAT TTT CAC TGT AGC				
	BMEI0535f	GCG CAT TCT TCG GTT ATG AA	*bp26*	450	6.25	(30)
	BMEI0536r	CGC AGG CGA AAA CAG CTA TAA				
	BMEII0843f	TTT ACA CAG GCA ATC CAG CA	*omp31*	1071	6.25	(31)
	BMEII0844r	GCG TCC AGT TGT TGT TGA TG				
	BMEI1436f	ACG CAG ACG ACC TTC GGT AT	*Deacetylase*	794	6.25	(32)
	BMEI1435r	TTT ATC CAT CGC CCT GTC AC				
	BMEII0428f	GCC GCT ATT ATG TGG ACT GG	*eryC*	587	6.25	(33)
	BMEII0428r	AAT GAC TTC ACG GTC GTTCG				
	BR0953f	GGA ACA CTA CGC CAC CTT GT	*ABC Transporter*	272	6.25	(34)
	BR0953r	GAT GGA GCA AAC GCT GAA G				
	BMEI0752f	CAG GCA AAC CCT CAG AAG C	*rpsL*	218	6.25	(35)
	BMEI0752r	GAT GTG GTA ACG CAC ACC AA				
	BMEII0987f	CGC AGA CAG TGA CCA TCA AA	*CRP Regulator*	152	6.25	(32)
	BMEII0987r	GTA TTC AGC CCC CGT TAC CT				

198

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

199 # Results

200 ## Brucellosis seroprevalence among slaughter cattle in Rwanda

201 Of the 300 cattle sera, 95.7% (287/300) were from females, while 4.3% (13/300) were from
202 males. Most animals, 89.7% (269/300) were adults while young animals represented 10.3%
203 (31/300). Twenty-seven percent [27.7%, (81/300)] of cattle sampled were local breed "Ankole",
204 67.0% (201/300) were crossbreeds and 5.3% (16/300) were Friesians. Samples were mainly
205 collected from high throughput abattoirs (n=280) compared to low throughput abattoirs (n=20).
206 The seroprevalence of brucellosis in parallel was 20.7% (62/300) and 2.9% (8/300) using RBT and
207 i-ELISA, respectively. The seroprevalence was 2.9%, (8/300) using both tests in parallel. Twenty-
208 one percent [21.1%, (59/280)] of the RBT positive cattle were sampled from high throughput
209 abattoirs, while 15.0% (3/20) were from the low throughput abattoirs. Eight samples that were
210 simultaneously positive on RBT and i-ELISA were collected from high throughput abattoirs
211 (Table 2). Considering the RBT results alone, the highest RBT positivity rate of 30.0%, (21/70) was
212 observed in the Eastern Province while the lowest 13.3%, (4/30) was recorded in the Kigali city
213 (Table 2). Twenty-one percent [21.6%, (58/269)] of RBT seropositive animals were adult, while
214 12.9%, (4/31) were young. Twenty percent [20.6%, (59/287)] of RBT seropositive animals were
215 female while 23.1%, (3/13) were young. The eight animals that were seropositive to both tests
216 were adult females. The RBT seropositivity recorded in different breeds of animals was as
217 follows: 15.7%, (13/83) for Ankole, 22.0%, (44/201) for crossbreds and 31.3%, (5/16) for Friesians
218 with no significant statistical difference ($p = 0.28$). However, there was a significant association (p

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

219 = 0.04) between seropositivity (RBT and i-ELISA) and breeds with Friesian being more

220 seropositive 12.5%, (2/16) than crossbreds 2.5%, (5/201) and Ankole 1.2%, (1/83) (Table 1).

Table 2: Univariate associations between animal characteristics, seropositivity, and isolation of *Brucella* spp. using ITS PCR assay on the DNA extracted from cultures of tissues of slaughtered cattle in Rwanda.

Variables	**Categories**	**Tested**	**RBT**			**i-ELISA**			**ITS PCR assay on culture isolates**		
			n^+ (%)	**OR**	***p*-value**	**n^+ (%)**	**OR**	***p*-value**	**n^+/N (%)**	**OR**	***p*-value**
Abattoirs	High thr.	280	59 (21.1)	0.8 – 1.1	0.78	8 (2.9)	0.1-0.2	1	16/78 (20.5)	0.69-1.16	0.68
	Low thr.	20	3 (15.0)			0 (0.0)			1/9 (11.1)		
Provinces	Eastern	70	21 (30.0)	-	0.17	3 (4.3)	-	0.37	2/14 (14.3)	-	0.95
	Kigali city	30	4 (13.3)			3 (6.0)			3/11 (27.3)		
	Northern	50	7 (14.0)			1 (1.3)			4/18 (22.2)		
	Southern	80	14 (17.5)			1 (1.4)			3/17 (17.6)		
	Western	70	16 (22.7)			1 (1.4)			5/27 (18.5)		
Age	Adults	269	58 (21.6)	0.8 – 1.0	0.35	8 (3.0)	0.95-0.99	1	17/77 (22.1)	0.69-0.88	0.19
	Young	31	4 (12.9)			0 (0.0)			0/10 (0.0)		
Sex	Females	287	59 (20.6)	0.8– 1.4	0.74	8 (2.8)	0.95-0.99	1	17/80 (21.3)	0.70-0.88	0.34
	Males	13	3 (23.1)			0 (0.0)			0/7 (0.0)		
Breed	Ankole	83	13 (15.7)	-	0.28	1 (1.2)	-	0.04	1/21 (4.8)	-	0.02
	Cross	201	44 (22.0)			5 (2.5)			13/61 (21.3)		
	Friesian	16	5 (31.3)			2 (12.5)			3/5 (60.0)		

RBT: Rose Bengal Test, i-ELISA: indirect enzyme-linked immunosorbent assay, Thr. = throughput; OR = odds ratio; CI = confidence interval; n+: number of positives; n+/N: number of positive animals over the total number of tested animals; %: percentage, NaN: not applicable.

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

227 **Bacteriology and the 16S-23S interspacer region (ITS) PCR assay**

228 Of the tissues (n=300) that were cultured onto the modified CITA medium, ITS PCR
229 confirmed 5.6% (17/300) (Fig 2). Therefore, the prevalence obtained by bacteriology, the gold
230 standard and confirmed by ITS PCR was 5.6% (17/300).

231 Fig 2. Agarose gel electrophoresis of the 16-23S interspacer region (ITS) PCR products amplified
232 from cultures of tissues from slaughtered cattle. Lanes M: DNA Gene Ruler 100bp plus
233 (Invitrogen, Pretoria, South Africa), lanes 1 – 7: amplification of a 214 bp sequence of the genus
234 *Brucella* spp., lane 8: negative control containing sterile water, lane 9: positive control with *B.*
235 *abortus* RF544.

236 **Differentiation of *Brucella* spp. by AMOS and Bruce-ladder PCR assays**

237 The AMOS PCR identified *B. melitensis* and *B. abortus* (n=3) mixed cultures, *B. abortus* (n=3)
238 and *B. melitensis* (n=5) (Fig 3) from the 17 *Brucella* cultures (impure culture). The Bruce-ladder
239 PCR assay identified *B. abortus* (n=5), *B. melitensis* (n=6) (Fig 4).

240 Fig 3. Agarose gel electrophoresis for AMOS PCR products amplified from cultures of tissues
241 from slaughtered cattle. Lanes M: Gene Ruler 100 pb plus (Invitrogen, ThermoFischer, South
242 Africa), lanes 1-4: *Brucella abortus* (496 bp), lanes 5-7: *B. melitensis* (731 bp), Lanes 9-10: mixed *B.*
243 *melitensis* and *B. abortus*, lane 11: negative control containing sterile water, lane 12: positive
244 control, *B. abortus* RF544, lane 13: positive control, *B. melitensis* rev 1.

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

245 Fig 4. Agarose gel electrophoresis for Bruce–ladder PCR products amplified from cultures of
246 tissues from slaughtered cattle. Lanes M: Gene Ruler 100 bp (Invitrogen, ThermoFischer, South
247 Africa); lanes 1-5: *B. abortus*; lanes 6-8: *B. melitensis*; lane 9: positive control, *B. suis* ZW45, lane 10:
248 positive control, *B. melitensis* rev 1, lane 11: *B. abortus* (REF 544), lane 12: positive control, *B. abortus*
249 S 19, lane 13: negative control with sterile water.

250 Culture prevalence amongst slaughtered cattle in Rwanda

251 The *Brucella* culture prevalence obtained by culture and confirmed by ITS PCR was 5.6%
252 (17/300). Of the *Brucella* spp. obtained by culture, 20.5% (16/78) were collected from high
253 throughput abattoirs, while 11.1% (1/9) were from low throughput abattoirs (OR = 0.69 – 1.16, p
254 = 0.68). There was no significant association between the isolation of *Brucella* spp. isolates and the
255 provinces of origin (p = 0.95), and the isolates were collected from the provinces as follows:
256 Eastern (14.3%, 2/14), Kigali city (27.3%, 3/11), Northern (22.2%, 4/18), Southern (17.6%, 3/17),
257 Western (18.5%, 5/27). All the *Brucella* obtained by culture (21.3%, 17/80) were adult (OR = 0.69 -
258 0.88, p = 0.20) and females (OR = 0.70 - 0.88, p = 0.34). There was a significant association between
259 the culture prevalence and breed (p = 0.02) with Friesians having more isolates (60.0%, 3/5),
260 followed by crossbreds (21.3%, 13/61) and Ankole (4.8%, 1/21) (Table 2).

261 The *Brucella* DNA detected by ITS, AMOS and Bruce-ladder PCR assays (100.0%,
262 11/11) were from cattle that were either seropositive to RBT or i-ELISA. Of these 11 *Brucella*
263 isolates, 10 were isolated from slaughtered cattle collected at high throughput abattoir.
264 The 11 *Brucella* isolates that were identified in provinces are as follows: Eastern (n = 1),

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

265 Kigali city (n = 2), Southern (n = 3), Western (n = 2), Northern (n = 3). The 11 *Brucella*
266 isolates stratified by breeds were Ankole (n = 1), crossbreds (n = 8) and Friesians (n = 2).
267 There was no significant difference between the category of abattoirs, provinces, age, sex
268 of animals and the detection by ITS, AMOS and Bruce-ladder PCR assays.

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

269 # Discussion

270 This is the first report of *B. abortus* and *B. melitensis* isolated from cultures of cattle tissues
271 collected from abattoirs. The overall seroprevalence obtained in this study among slaughtered
272 cattle selected from all the thirty districts of Rwanda (2.9% for RBT and i-ELISA) was lower than
273 the culture prevalence of 5.6% (17/300), which is the gold standard. The fact that the lower
274 sensitivity culture method is higher than the seroprevalence is a clear indication that the
275 confirmatory i-ELISA test must be validated for bovine in Rwanda as the cut-off values were
276 determined in developed countries with low brucellosis prevalence and thus clearly
277 underestimate the prevalence due to high cut-off values.

278 The overall seroprevalence of 2.9% was also lower than the rates reported in Rwanda in
279 different studies that were conducted at farm level (16, 17, 36). However, the seroprevalence
280 obtained in this study is comparable with the rate (3.4%) reported at Gaoundere municipal
281 abattoir in Cameroun using RBT and i-ELISA (37), and the 3.9% reported among slaughtered
282 cattle in Nigeria (38), and the 5.5% reported among slaughtered cattle in Gauteng province, South
283 Africa (39).This suggests that the seroprevalence rates observed in abattoirs are usually lower
284 compared to the seroprevalence recorded at the farm level which usually focuses on endemic
285 zones while slaughtered cattle come from various locations (endemic and non-endemic zones).

286 Friesians were more likely to be seropositive in this study and was consistent with earlier
287 studies in Pakistan where Holstein and Friesian cattle were more seropositive than indigenous
288 breeds (40), and in Ethiopia (41). This supports that exotic pure breeds like Friesians are more
289 susceptible to brucellosis than crossbreeds and indigenous breeds (42) or were introduced in the

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

290 herd with chronic infections with seronegative status but being chronically infected (12, 43).
291 When the acute brucellosis phase has passed, the infection stabilizes with the acquisition of herd
292 immunity leading to less infectious discharges and non-visible symptoms (44).

293 The mixed infection caused by *B. abortus* and *B. melitensis* and the isolation of *B. melitensis*
294 from slaughtered cattle indicate the cross-infection between both *Brucella* spp. and mixed farming
295 of cattle and goats or sheep. The mixed infection and mixed farming were reported in our study
296 that identified both pathogens in aborting goat flock in Rwanda (unpublished data). The co-
297 infection of *B. abortus* and *B. melitensis* has also been reported in slaughtered cattle in South Africa
298 (39). The isolation of *B. melitensis* in slaughtered cattle poses a risk to abattoir workers and
299 consumers of of contaminated milk and milk products as *B. melitensis* and *B. abortus* cause severe
300 brucellosis in humans (45, 46). There is a need for improvement in brucellosis control using
301 vaccination as well as test-and-slaughter, coupled with raising awareness of all occupational
302 groups as education was associated with a high awareness of brucellosis in Rwanda (17).

303 Both AMOS and Bruce-ladder PCR assays identified *B. abortus* and *B. melitensis* with the
304 *B. abortus* being either biovars 1, 2, or 4 (identified by AMOS PCR) which will be identified in the
305 future after purification of cultures using biotyping. A previous study *B. abortus* bv. 3 was
306 identified in humans and animals in 1987 in Rwanda (20). *B. abortus* bv. 3 and *B. melitensis* bv. 1
307 were reported in neighboring Uganda (47), Tanzania (48), Kenya (49) and South Africa (39).
308 Biotyping of *B. abortus* biovars is complex as characteristic typical for *B. abortus* bv .1, except CO_2
309 requirement for growth (50). However, the *B. abortus* bv. 3 ref strain Tulya isolated from human
310 patient in Uganda grows in the absence of CO_2 and has been observed to occur within some

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

311 biovars and changes with OIE biotyping profile (9, 48). Hence classifying *B. abortus* bv. 3 strains
312 should be carefully considered. Purifying and biotyping these cultures will be able to identify the
313 biovar(s) and molecular characterization of the strains will allow trace back studies. *Brucella*
314 *abortus* and *B. melitensis* isolated in this study could originate from neighboring countries due to
315 repatriation of Rwandans and their livestock from Uganda and Tanzania as well as importation
316 of improved cattle breeds from various countries cannot be eliminated despites testing
317 procedures (12).

318 *Brucella* spp. were mostly isolated from adult females, and this is not surprising as cattle
319 industry focuses mostly on dairy production while commercial beef production is emerging in
320 Rwanda. Almost half (47.0%) of the milk produced in 2008 was destined for sale at the informal
321 market, with 16.0% for home consumption, while 35.0% represented spoiled milk (51). Therefore,
322 the occurrence of brucellosis in slaughtered cattle is not only a risk to abattoir workers but also
323 consumers of milk and milk products. Several cattle and tons of beef are sold to Bukavu and
324 Goma, the towns of the Democratic Republic of Congo neighbouring Rwanda where the
325 brochettes of the udder are expensive and frequently consumed. The udder is among the
326 predilection sites of *Brucella* spp. (52, 53) and meat inspection should focus on the udder. Meat
327 inspection provides safe meat and contributes to the monitoring and surveillance for animal
328 infectious diseases and zoonoses (54). Furthermore, these brochettes should be consumed well
329 done. It is also important to raise the awareness of involved stakeholders through education
330 campaigns or media.

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

331 # Conclusions

332 This study found the seroprevalence of brucellosis to be lower than the gold standard rate
333 indicating that cut-off points of i-ELISA determined in Europe with brucellosis free status or low
334 prevalence, should be optimized for Rwanda as also reported by Mathew *et al.* (2015). This study
335 identified *B. abortus* and *B. melitensis* as well as mixed infection in slaughtered cattle which is as a
336 result of the mixed livestock farming practice in Rwanda. These infections pose a risk of exposure
337 potential to handlers of cattle, carcasses and consumers of unpasteurized milk and milk products.
338 Thus, vaccination and test-and-slaughter would significantly contribute to mitigate the disease.
339 Furthermore, the introduction of an annual brucellosis-free certificate for large herds would
340 contribute to mitigating brucellosis in the country.

341 # Author's contributions

342 Conceptualization, JBN, and HvH; methodology, JBN, and HvH; Formal analysis JBN;
343 Investigation and data collection, JBN; Writing—original draft preparation, JBN; writing—review
344 and editing, JBN, IEM, FBK, and HvH; Supervision, HvH, and FBK; Project administration, HvH;
345 Resources, HvH; Funding acquisition, HvH. All authors have read and approved the manuscript.

346 # Funding

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

347 This research was funded by the Institute of Tropical Medicine Antwerp, Belgium through a grant
348 agreement with the Department of Veterinary Tropical Diseases, University of Pretoria, grant
349 number ITM FA4.

350 # Acknowledgments

351 The authors would like to acknowledge the Institute of tropical medicine, Belgium, and the
352 Department of Veterinary Tropical Disease, South Africa, for funding the project. Our
353 acknowledgments also go to the National Reference Laboratory, Department of Veterinary
354 Services, and the University of Rwanda for the facilitation of this study. We also thank abattoir
355 managers, inspectors and other abattoir workers, laboratory staff at NRL, and RAB for their
356 assistance and good cooperation.

357 # Conflict of interest

358 The authors declare that there are no conflicts of interest. The funders had no role in the design
359 of the study; in the collection, analyses, or interpretation of data, in the writing of the manuscript,
360 or in the decision to publish the results.

361 # Availability of Data

362 All data will be available in the supplementary material of this journal.

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

363 # References

364 1. McDermott J, Grace D, Zinsstag J. Economics of brucellosis impact and control in low-
365 income countries. Revue Scientifique Et Technique-Office International Des Epizooties.
366 2013;32(1):249-61.
367 2. Singh BB, Dhand NK, Gill JP. Economic losses occurring due to brucellosis in Indian
368 livestock populations. Prev Vet Med. 2015;119(3-4):211-5.
369 3. Moreno E, Stackebrandt E, Dorsch M, Wolters J, Busch M, Mayer H. *Brucella abortus* 16S
370 rRNA and lipid A reveal a phylogenetic relationship with members of the alpha-2 subdivision of
371 the class Proteobacteria. Journal of bacteriology. 1990;172(7):3569-76.
372 4. Alton GG, Jones LM, Pietz DE. Laboratory techniques in brucellosis. 2d ed. ed. Geneva
373 [Albany, N.Y.]: World Health Organization ; [Available from Q Corp.]; 1975.
374 5. Corbel MJ. Brucellosis: an overview. Emerging infectious diseases. 1997;3(2):213-21.
375 6. Verger J-M, Grimont F, Grimont PA, Grayon M. *Brucella*, a monospecific genus as shown
376 by deoxyribonucleic acid hybridization. International Journal of Systematic and Evolutionary
377 Microbiology. 1985;35(3):292-5.
378 7. Bricker BJ, Halling SM. Differentiation of *Brucella-Abortus-Bv-1*, *Brucella-Abortus-Bv-2*, and
379 *Brucella-Abortus-Bv-4*, *Brucella-Melitensis*, *Brucella-Ovis*, and *Brucella-Suis-Bv-1* by PCR. Journal of
380 clinical microbiology. 1994;32(11):2660-6.
381 8. Ficht T, Bearden S, Sowa B, Marquis H. Genetic variation at the *omp2* porin locus of the
382 brucellae: species-specific markers. Molecular microbiology. 1990;4(7):1135-42.
383 9. OIE. Brucellosis (*Brucella abortus, Brucella melitensis,* and *Brucella suis*) Manual of
384 Diagnostic Tests and Vaccines for Terrestrial Animals 2021. Volumes 1, 2 and 3. Terrestrial
385 Manual 8th Edition, 2021 ed. Paris, France World Organisation for Animal Health 2021. p. 355 -
386 98.
387 10. Kaufmann AF, Fox MD, Boyce JM, Anderson DC, Potter ME, Martone WJ, et al. Airborne
388 spread of brucellosis. Annals of the New York Academy of Sciences. 1980;353(1):105-14.
389 11. Corbel MJ. Brucellosis in humans and animals. Corbel MJ, editor2006. ix + 89 pp. p.
390 12. Akakpo A, Bornarel P. Epidemiology of animal brucellosis in tropical Africa: clinical,
391 serological and bacteriological surveys. Revue Scientifique et Technique de l'OIE (France). 1987.
392 13. Garcia-Yoldi D, Marin CM, de Miguel MJ, Munoz PM, Vizmanos JL, Lopez-Goni I.
393 Multiplex PCR assay for the identification and differentiation of all *Brucella* species and the
394 vaccine strains *Brucella abortus* S19 and RB51 and *Brucella melitensis* Rev1. Clinical chemistry.
395 2006;52(4):779-81.
396 14. Lopez-Goni I, Garcia-Yoldi D, Marin CM, de Miguel MJ, Munoz PM, Blasco JM, et al.
397 Evaluation of a multiplex PCR assay (Bruce-ladder) for molecular typing of all Brucella species,
398 including the vaccine strains. Journal of clinical microbiology. 2008;46(10):3484-7.
399 15. Ducrotoy MJ, Bardosh KL. How do you get the Rose Bengal Test at the point-of-care to
400 diagnose brucellosis in Africa? The importance of a systems approach. The Fate of Neglected
401 Zoonotic Diseases2017. p. 33-9.

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

402 16. Ndazigaruye G, Mushonga B, Kandiwa E, Samkange A, Segwagwe BE. Prevalence and
403 risk factors for brucellosis seropositivity in cattle in Nyagatare District, Eastern Province,
404 Rwanda. Journal of the South African Veterinary Association. 2018;89(0):e1-e8.
405 17. Ntivuguruzwa JB, Kolo FB, Gashururu RS, Umurerwa L, Byaruhanga C, van Heerden H.
406 Seroprevalence and Associated Risk Factors of Bovine Brucellosis at the Wildlife-Livestock-
407 Human Interface in Rwanda. Microorganisms. 2020;8(10):1553.
408 18. Gafirita J, Kiiza G, Murekatete A, Ndahayo LL, Tuyisenge J, Mashengesho V, et al.
409 Seroprevalence of Brucellosis among Patients Attending a District Hospital in Rwanda. The
410 American Journal of Tropical Medicine and Hygiene. 2017;97(3):831-5.
411 19. Rujeni N, Mbanzamihigo L. Prevalence of brucellosis among women presenting with
412 abortion/stillbirth in Huye, Rwanda. Journal of Tropical Medicine. 2014;2014:740479-Article ID
413 20. Verger JM, Grayon M. [Characteristics of 273 strains of *Brucella abortus* of African origin].
414 Dev Biol Stand. 1984;56:63-71.
415 21. Minagri MoAaAR. Annual Report 2018 - 2019 Kigali, Rwanda MINAGRI; 2019 November
416 2019.
417 22. Dohoo IR, Martin SW, Stryhn H. Veterinary epidemiologic research. Charlotte, P.E.I.:
418 VER, Inc.; 2009.
419 23. Pope GW. Determining the age of farm animals by their teeth: US Department of
420 Agriculture; 1934.
421 24. Chisi SL, Marageni Y, Naidoo P, Zulu G, Akol GW, Van Heerden H. An evaluation of
422 serological tests in the diagnosis of bovine brucellosis in naturally infected cattle in KwaZulu-
423 Natal province in South Africa. Journal of the South African Veterinary Association.
424 2017;88(0):e1-e7.
425 25. Nielsen K. Diagnosis of brucellosis by serology. Veterinary microbiology. 2002;90(1-
426 4):447-59.
427 26. Ledwaba MB, Matle I, Van Heerden H, Ndumnego OC, Gelaw AK. Investigating selective
428 media for optimal isolation of *Brucella* spp. in South Africa. Onderstepoort Journal of Veterinary
429 Research. 2020;87(1):1-9.
430 27. Keid LB, Soares RM, Vasconcellos SA, Chiebao DP, Salgado VR, Megid J, et al. A
431 polymerase chain reaction for detection of *Brucella canis* in vaginal swabs of naturally infected
432 bitches. Theriogenology. 2007;68(9):1260-70.
433 28. Garcia-Yoldi D, Marín C, Lopez-Goni I. Restriction site polymorphisms in the genes
434 encoding new members of group 3 outer membrane protein family of Brucella spp. FEMS
435 microbiology letters. 2005;245(1):79-84.
436 29. Vemulapalli R, McQuiston JR, Schurig GG, Sriranganathan N, Halling SM, Boyle SM.
437 Identification of an IS711 Element Interrupting the *wboA* Gene of *Brucella abortus* Vaccine Strain
438 RB51 and a PCR Assay To Distinguish Strain RB51 from Other *Brucella* Species and Strains.
439 Clinical and Diagnostic Laboratory Immunology. 1999;6(5):760-4.
440 30. Cloeckaert A, Grayon M, Grepinet O. An IS711 element downstream of the bp26 gene is
441 a specific marker of *Brucella spp.* isolated from marine mammals. Clinical and Diagnostic
442 Laboratory Immunology. 2000;7(5):835-9.

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

443 31. Vizcaino N, Verger J-M, Grayon M, Zygmunt MS, Cloeckaert A. DNA polymorphism at
444 the omp-31 locus of *Brucella* spp.: evidence for a large deletion in *Brucella abortus*, and other
445 species-specific markers. Microbiology. 1997;143(9):2913-21.
446 32. Rajashekara G, Glasner JD, Glover DA, Splitter GA. Comparative whole-genome
447 hybridization reveals genomic islands in *Brucella* species. Journal of bacteriology.
448 2004;186(15):5040-51.
449 33. Sangari FJ, García-Lobo JM, Agüero J. The *Brucella abortus* vaccine strain B19 carries a
450 deletion in the erythritol catabolic genes. FEMS Microbiology Letters. 1994;121(3):337-42.
451 34. Halling SM, Peterson-Burch BD, Bricker BJ, Zuerner RL, Qing Z, Li L-L, et al. Completion
452 of the genome sequence of *Brucella abortus* and comparison to the highly similar genomes of
453 *Brucella melitensis* and *Brucella suis*. Journal of Bacteriology. 2005;187(8):2715-26.
454 35. Cloeckaert A, Grayon M, Grépinet O. Identification of *Brucella melitensis* vaccine strain
455 Rev.1 by PCR-RFLP based on a mutation in the rpsL gene. Vaccine. 2002;20(19):2546-50.
456 36. Rujeni N, Gasogo A, Mbanzamihigo L. Contribution to the Study of the Prevalence of
457 Brucellosis in Rwanda. Case Study of Huye District. International Journal of Infectious Diseases.
458 2008;12(1):e128.
459 37. Awah-Ndukum J, Mouiche MMM, Bayang HN, Ngwa VN, Assana E, Feussom KJM, et
460 al. Seroprevalence and Associated Risk Factors of Brucellosis among Indigenous Cattle in the
461 Adamawa and North Regions of Cameroon. Veterinary medicine international.
462 2018;2018:3468596.
463 38. Akinseye VO, Adesokan HK, Ogugua AJ, Adedoyin FJ, Otu PI, Kwaghe AV, et al. Sero-
464 epidemiological survey and risk factors associated with bovine brucellosis among slaughtered
465 cattle in Nigeria. Onderstepoort Journal of Veterinary Research. 2016;83(1):1-7.
466 39. Kolo FB, Adesiyun AA, Fasina FO, Katsande CT, Dogonyaro BB, Potts A, et al.
467 Seroprevalence and characterization of *Brucella* species in cattle slaughtered at Gauteng abattoirs,
468 South Africa. Veterinary Medicine and Science. 2019;5(4):545-55.
469 40. Mangi M, Kamboh A, Rind R, Dewani P, Nizamani Z, Mangi A, et al. Seroprevalence of
470 brucellosis in Holstein-Friesian and indigenous cattle breeds of Sindh Province. Pakistan J Anim
471 Health Prod. 2015;3(4):82-7.
472 41. Omer M, Skjerve E, Woldehiwet Z, Holstad G. Risk factors for *Brucella spp*. infection in
473 dairy cattle farms in Asmara, State of Eritrea. Preventive Veterinary Medicine. 2000;46(4):257-65.
474 42. Akhtar R, Iqbal MZ, Ullah A, Ali MM, Zahid B, Ijaz M, et al. Comparative association of
475 *slc11a1* (*Nramp1)* gene with susceptibility and resistance to brucellosis in various cattle and
476 buffaloes breeds of Pakistan. Pak Vet J. 2019;39:612-4.
477 43. Roux J. Epidémiologie et prévention de la brucellose. Bulletin of the World Health
478 Organization. 1979;57(2):179.
479 44. Ducrotoy M, Bertu WJ, Matope G, Cadmus S, Conde-Alvarez R, Gusi AM, et al.
480 Brucellosis in Sub-Saharan Africa: Current challenges for management, diagnosis and control.
481 Acta Tropica. 2017;165:179-93.
482 45. Sadler WW. Present evidence on the role of meat in the epidemiology of human
483 brucellosis. American Journal of Public Health and the Nations Health. 1960;50(4):504-14.

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

484 46. Sayour AE, Elbauomy E, Abdel-Hamid NH, Mahrous A, Carychao D, Cooley MB, et al.
485 MLVA fingerprinting of *Brucella melitensis* circulating among livestock and cases of sporadic
486 human illness in Egypt. Transboundary and emerging diseases. 2020;67(6):2435-45.
487 47. Mugizi DR, Muradrasoli S, Boqvist S, Erume J, Nasinyama GW, Waiswa C, et al. Isolation
488 and molecular characterization of *Brucella* isolates in cattle milk in Uganda. BioMed research
489 international. 2015;2015.
490 48. Mathew C, Stokstad M, Johansen T, Klevar S, Mdegela R, Mwamengele G, et al. First
491 isolation, identification, phenotypic and genotypic characterization of *Brucella abortus* biovar 3
492 from dairy cattle in Tanzania. BMC veterinary research. 2015;11(1):156.
493 49. Muendo EN, Mbatha PM, Macharia J, Abdoel TH, Janszen PV, Pastoor R, et al. Infection
494 of cattle in Kenya with *Brucella abortus* biovar 3 and *Brucella melitensis* biovar 1 genotypes. Tropical
495 animal health and production. 2012;44(1):17-20.
496 50. Alton GG, Jones LM, Angus RD, Verger JM. Techniques for the brucellosis laboratory1988.
497 190 pp. p.
498 51. Techoserve. The Dairy Value Chain in Rwanda Kigali Technoserve 2008 [cited 2020
499 October 8]. Available from:
500 https://cgspace.cgiar.org/bitstream/handle/10568/2410/Dairy%20Value%20Chain%20Rwanda%2
501 0Report.pdf;sequence=1.
502 52. Caine L-A, Nwodo UU, Okoh AI, Green E. Molecular characterization of *Brucella* species
503 in cattle, sheep and goats obtained from selected municipalities in the Eastern Cape, South Africa.
504 Asian Pacific Journal of Tropical Disease. 2017;7(5):293-8.
505 53. Fero E, Juma A, Koni A, Boci J, Kirandjiski T, Connor R, et al. The seroprevalence of
506 brucellosis and molecular characterization of Brucella species circulating in the beef cattle herds
507 in Albania. PloS one. 2020;15(3):e0229741.
508 54. Vågsholm I. Control, monitoring and surveillance of animal health and animal infectious
509 diseases at the slaughterhouse. Meat Inspection and Control in the Slaughterhouse. 2014:249-76.

510

Figure bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Click here to access/download;Figure;Figure 1.docx



Fig 1. Map of provinces and districts of Rwanda with location (red asterisks) of abattoirs visited during this study

Figure

Click here to access/download;Figure;Figure 2.docx

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



Fig 2. Agarose gel electrophoresis of the 16-23S interspacer region (ITS) PCR products amplified from cultures of tissues from slaughtered cattle. Lanes M: DNA GeneRuler 100bp plus (Invitrogen, Pretoria, South Africa), lanes 1 – 7: amplification of a 214 bp sequence of the genus *Brucella* spp., lane 8: negative control containing sterile water, lane 9: positive control with *B. abortus* RF544.

Figure bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
Click here to access/download;Figure;Figure 3.docx



Fig 3. Agarose gel electrophoresis for AMOS PCR products amplified from cultures of tissues from slaughtered cattle. Lanes M: Gene Ruler 100 pb plus (Invitrogen, ThermoFischer, South Africa), lanes 1-4: *Brucella abortus* (496 bp), lanes 5-7: *B. melitensis* (731 bp), Lanes 9-10: mixed *B. melitensis* and *B. abortus*, lane 11: negative control containing sterile water, lane 12: positive control, *B. abortus* RF544, lane 13: positive control, *B. melitensis* rev 1.

Figure bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Click here to access/download;Figure;Figure 4.docx



Fig 4. Agarose gel electrophoresis for Bruce–ladder PCR products amplified from cultures of tissues from slaughtered cattle. Lanes M: Gene Ruler 100 bp (Invitrogen, ThermoFischer, South Africa); lanes 1-5: *B. abortus*; lanes 6-8: *B. melitensis*; lane 9: positive control, *B. suis* ZW45, lane 10: positive control, *B. melitensis* rev 1, lane 11: *B. abortus* (REF 544), lane 12: positive control, *B. abortus* S 19, lane 13: negative control with sterile water.

bioRxiv preprint doi: https://doi.org/10.1101/2021.12.07.471573; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



Click here to access/download
Supporting Information
Raw data for PLOS ONE.xlsx